REVOLUTION MEDICINES INC (RVMD)

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Underwriters’ full exercise of option brings gross proceeds to $862.5 million...

Revolution Medicines Larger Than S&P 500 Component Celanese

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302...

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC ...

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals...

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy...

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time...

Revolution Medicines Larger Than S&P 500 Component FMC

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination...

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders....

The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

The 3 Most Undervalued Biotech Stocks to Buy in June 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024

RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.

RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revolution Medicines (NASDAQ:RVMD) just reported results for the first quarter ...

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time...

Revolution Medicines Larger Than S&P 500 Component Bio-Rad Laboratories

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond...